GelStat Corporation (OTCPK: GSAC)
Health Care · Pharmaceuticals · US
$0.00
+25.00% today · -14.3% 1Y
GelStat Corporation (OTCPK: GSAC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.12M and employs 2 people.
Over the last twelve months the share price has lost 14.3%, trading between 0.00 and 0.00.
Tweenvest scores GelStat Corporation across four factors: quality 21/100, value 83/100. Its strongest factor is value.
GSAC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.12M
- Revenue (TTM)
- $363.53K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.64
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 3.74B
- Employees
- 2
- Next earnings
- —
About GelStat Corporation
GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) and other non-prescription health solutions. Its diverse product portfolio addresses various common health concerns, featuring: GelStat Migraine, a patented remedy targeting migraine headache pain; Chews 2 Lose, an appetite-controlling gum designed to assist with weight management; All Natural Speed, formulated as an energy booster; and GelStat Sleep, intended to alleviate sleep disturbances and their related symptoms. GelStat distributes its solutions through a comprehensive network, reaching retailers, wholesalers, specialized distributors, and catalog merchandisers. This is achieved both through direct sales and via independent sales brokerage agreements. The corporation maintains its principal office in Palm City, Florida.
- ISIN
- US3685331056
- Founded
- 2002
- Listed since
- Feb 9, 1996
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.